PENTHOXYFILLINE SEBAGAI TERAPI KOMPLEMENTER CHRONIC KIDNEY DISEASE
Abstract
Chronic kidney disease (CKD) merupakan penyebab kematian paling umum ke-18 setiap tahunnya, yang sering dikaitkan dengan usia tua, diabetes, hipertensi, obesitas, serta penyakit kardiovaskular. Pengobatan CKD yang ada sekarang dirasa kurang efektif karena hanya sebatas memperlambat progresivitasnya. Pentoxyfilline (PTX) merupakan salah satu terapi yang dapat dijadikan terapi komplementer pada CKD. PTX dapat memberikan efek renoprotektif. PTX juga dapat mengatasi proteinuria pada penderita diabetic nephropathy. Maka dari itu PTX dapat digunakan sebagai terapi komplementer pada penderita CKD.
Downloads
Download data is not yet available.
References
1. Levey AS, Coresh J. Chronic kidney disease. Lancet [Internet]. 2012;379(9811):165–80. Available from: http://dx.doi.org/10.1016/S0140-6736(11)60178-5
2. Gansevoort RT, Correa-rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF. Global Kidney Disease 5 Chronic kidney disease and cardiovascular risk : epidemiology , mechanisms , and prevention. Lancet [Internet]. 2013;382(9889):339–52. Available from: http://dx.doi.org/10.1016/S0140-6736(13)60595-4
3. Webster AC, Nagler E V, Morton RL, Masson P. Chronic kidney disease. Lancet [Internet]. 2017;389(10075):1238–52. Available from: http://dx.doi.org/10.1016/S0140-6736(16)32064-5
4. Abdel-kader K, Unruh ML, Weisbord SD. Symptom Burden , Depression , and Quality of Life in Chronic and End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2009;4:1057–64.
5. Jha V, Garcia-garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al.. Global Kidney Disease 3 Chronic kidney disease : global dimension and perspectives. Lancet [Internet]. 2013;382(9888):260–72. Available from: http://dx.doi.org/10.1016/S0140-6736(13)60687-X
6. Day WK. Chronic kidney disease [Internet]. https://www.worldkidneyday.org/. 2019 [cited 2019 Dec 10]. p. 1. Available from: https://www.worldkidneyday.org/facts/chronic-kidney-disease/
7. Wang J, Zhang L, Tang SC, Kashihara N, Kim Y, Togtokh A, et al.. Disease burden and challenges of chronic kidney disease in North and East Asia. Kidney Int [Internet]. 2018;94(1):22–5. Available from: https://doi.org/10.1016/j.kint.2017.12.022
8. Consortium CKDP. Association of estimated glomerular fi ltration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts : a collaborative meta-analysis. Lancet [Internet]. 2010;375(9731):2073–81. Available from: http://dx.doi.org/10.1016/S0140-6736(10)60674-5
9. Velde M Van Der, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al.. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality . A collaborative meta-analysis of high-risk population cohorts. Kidney Int [Internet]. 2011;79(12):1341–52. Available from: http://dx.doi.org/10.1038/ki.2010.536
10. Leporini C, Pisano A, Russo E, Arrigo GD, Sarro G De, Coppolino G, et al.. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients : A systematic review and meta-analysis. Pharmacol Res [Internet]. 2016;107:315–32. Available from: http://dx.doi.org/10.1016/j.phrs.2016.03.001
11. de Morales AM, Goicoechea M, Verde E, Carbayo J, Barbieri D, Delgado A, Verdalles U, de Jose AP, Luño J. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology. 2019 Apr 4:1-7.
12. Fraser DSS dan Blakeman T. Chronic kidney disease: identification and management in primary care. Dovepress.2016;7:21-32.
13. NICE Clinical Guidelines 182. Chronic kidney disease: Early Identification and Management of Chronic kidney disease in Adults in Primary and Secondary Care. London: National Institute of Health and Care Excellence; 2014.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic kidney disease. Kidney International Supplements. 2013;3:1–150.
15. Chronic kidney disease Prognosis Consortium; Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
16. Radhakrishnan J, Remuzzi G, Saran R, et al. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int. 2014;86(2):246–250
17. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996;155:1053-9
18. Salhiyyah K, Senanayake E, Abdel-Hadi M et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012;1:CD005262.
19. McCarty MF, O’Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart 2016;3:e000365
20. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997;29:181-96.
21. Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF. Pentoxifylline for renal protection in diabetic kidney disease. A Model of old drugs for new horizons. Journal of clinical medicine. 2019 Mar;8(3):287.
22. Navarro JF, Milena FJ, Mora C, León C, García J (2006) Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26(6):562–570
23. Sönmez MF, Dündar M (2016) Ameliorative effects of pentoxifylline
on NOS induced by diabetes in rat kidney. Ren Fail 38(4):605–613
24. Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C. Effects of pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes care. 2018 Aug 1;41(8):1817-20.
25. Oliaei F, Hushmand S, Khafri S, Baradaran M. Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Caspian journal of internal medicine. 2011;2(4):309.
26. Ghorbani A, Omidvar B, Beladi-Mousavi SS, Beladi Mousavi SS, Lak E, Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrología (English Edition). 2012 Nov 1;32(6):790-6.
27. Navarro-González JF, Mora-Fernández C, de Fuentes MM, Chahin J, Méndez ML, Gallego E, Macía M, del Castillo N, Rivero A, Getino MA, García P. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. Journal of the American Society of Nephrology. 2015 Jan 1;26(1):220-9.
28. Han SJ, Kim HJ, Kim DJ, Sheen SS, Chung CH, Ahn CW, Kim SH, Cho YW, Park SW, Kim SK, Kim CS. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetology & metabolic syndrome. 2015 Dec;7(1):64.
2. Gansevoort RT, Correa-rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF. Global Kidney Disease 5 Chronic kidney disease and cardiovascular risk : epidemiology , mechanisms , and prevention. Lancet [Internet]. 2013;382(9889):339–52. Available from: http://dx.doi.org/10.1016/S0140-6736(13)60595-4
3. Webster AC, Nagler E V, Morton RL, Masson P. Chronic kidney disease. Lancet [Internet]. 2017;389(10075):1238–52. Available from: http://dx.doi.org/10.1016/S0140-6736(16)32064-5
4. Abdel-kader K, Unruh ML, Weisbord SD. Symptom Burden , Depression , and Quality of Life in Chronic and End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2009;4:1057–64.
5. Jha V, Garcia-garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al.. Global Kidney Disease 3 Chronic kidney disease : global dimension and perspectives. Lancet [Internet]. 2013;382(9888):260–72. Available from: http://dx.doi.org/10.1016/S0140-6736(13)60687-X
6. Day WK. Chronic kidney disease [Internet]. https://www.worldkidneyday.org/. 2019 [cited 2019 Dec 10]. p. 1. Available from: https://www.worldkidneyday.org/facts/chronic-kidney-disease/
7. Wang J, Zhang L, Tang SC, Kashihara N, Kim Y, Togtokh A, et al.. Disease burden and challenges of chronic kidney disease in North and East Asia. Kidney Int [Internet]. 2018;94(1):22–5. Available from: https://doi.org/10.1016/j.kint.2017.12.022
8. Consortium CKDP. Association of estimated glomerular fi ltration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts : a collaborative meta-analysis. Lancet [Internet]. 2010;375(9731):2073–81. Available from: http://dx.doi.org/10.1016/S0140-6736(10)60674-5
9. Velde M Van Der, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al.. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality . A collaborative meta-analysis of high-risk population cohorts. Kidney Int [Internet]. 2011;79(12):1341–52. Available from: http://dx.doi.org/10.1038/ki.2010.536
10. Leporini C, Pisano A, Russo E, Arrigo GD, Sarro G De, Coppolino G, et al.. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients : A systematic review and meta-analysis. Pharmacol Res [Internet]. 2016;107:315–32. Available from: http://dx.doi.org/10.1016/j.phrs.2016.03.001
11. de Morales AM, Goicoechea M, Verde E, Carbayo J, Barbieri D, Delgado A, Verdalles U, de Jose AP, Luño J. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. Journal of Nephrology. 2019 Apr 4:1-7.
12. Fraser DSS dan Blakeman T. Chronic kidney disease: identification and management in primary care. Dovepress.2016;7:21-32.
13. NICE Clinical Guidelines 182. Chronic kidney disease: Early Identification and Management of Chronic kidney disease in Adults in Primary and Secondary Care. London: National Institute of Health and Care Excellence; 2014.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic kidney disease. Kidney International Supplements. 2013;3:1–150.
15. Chronic kidney disease Prognosis Consortium; Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
16. Radhakrishnan J, Remuzzi G, Saran R, et al. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int. 2014;86(2):246–250
17. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996;155:1053-9
18. Salhiyyah K, Senanayake E, Abdel-Hadi M et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012;1:CD005262.
19. McCarty MF, O’Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart 2016;3:e000365
20. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997;29:181-96.
21. Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF. Pentoxifylline for renal protection in diabetic kidney disease. A Model of old drugs for new horizons. Journal of clinical medicine. 2019 Mar;8(3):287.
22. Navarro JF, Milena FJ, Mora C, León C, García J (2006) Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26(6):562–570
23. Sönmez MF, Dündar M (2016) Ameliorative effects of pentoxifylline
on NOS induced by diabetes in rat kidney. Ren Fail 38(4):605–613
24. Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C. Effects of pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes care. 2018 Aug 1;41(8):1817-20.
25. Oliaei F, Hushmand S, Khafri S, Baradaran M. Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Caspian journal of internal medicine. 2011;2(4):309.
26. Ghorbani A, Omidvar B, Beladi-Mousavi SS, Beladi Mousavi SS, Lak E, Vaziri S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrología (English Edition). 2012 Nov 1;32(6):790-6.
27. Navarro-González JF, Mora-Fernández C, de Fuentes MM, Chahin J, Méndez ML, Gallego E, Macía M, del Castillo N, Rivero A, Getino MA, García P. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. Journal of the American Society of Nephrology. 2015 Jan 1;26(1):220-9.
28. Han SJ, Kim HJ, Kim DJ, Sheen SS, Chung CH, Ahn CW, Kim SH, Cho YW, Park SW, Kim SK, Kim CS. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetology & metabolic syndrome. 2015 Dec;7(1):64.
Published
2021-08-01
How to Cite
WIDIANANTARA, I Made; DEWI, Ni Nyoman Gita Kharisma; PURWANINGRUM, Ni Made Ari.
PENTHOXYFILLINE SEBAGAI TERAPI KOMPLEMENTER CHRONIC KIDNEY DISEASE.
Essential: Essence of Scientific Medical Journal, [S.l.], v. 19, n. 1, p. 22-26, aug. 2021.
ISSN 2655-6472.
Available at: <https://ojs.unud.ac.id/index.php/essential/article/view/59059>. Date accessed: 22 nov. 2024.
Section
Artikel Tinjauan Pustaka
SUBMISSION
